alpha-MSH analogue raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-02-03 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Alpha-MSH analogue with a lactam ring |
| Molecular formula | C50H69N15O9 | Commonly cited value for the neutral peptide |
| Molecular weight | 1024.18 g/mol | Calculated for the free molecule |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water, DMSO and ethanol | Dissolution in pure water is often slow |
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
==== Film criticism ==== A significant number of users on TikTok, such as Juju Green, create content surrounding film criticism and easter eggs. However, as reported by The New York Times, these people often do not see themselves necessarily as film critics. These creators would often attend red carpet premieres of movies and interview the celebrities in attendance, which was the subject of significant debate as some considered the questions the creators asked to be disrespectful. By 2022, TikTok released a Showbiz List, highlighting individuals who were having a larger impact on the film industry. During the 2023 SAG-AFTRA strike, such influencers were told that they would be denied future entry into the union if they partnered with struck studios. This led many creators to stop creating new content which they were not already contractually obligated to create. Creators who posted saying that they would not be changing their content, such as Green, were met with significant criticism.
Going back more than 350 years, the first landmark description was of general blood circulation by William Harvey in 1628, which formed the anatomical basis for intravenous infusions. Investigations during the following centuries demonstrated solutions containing electrolytes and glucose could be given intravenously. The accumulated knowledge of protein metabolism formed the basis for studies on intravenous nutrition with protein hydrolysates, peptides, and amino acids. Robert Elman's observation in the late 1930s that amino acids in the form of protein hydrolysate could be administered safely was the first major step toward TPN. During the following years, major efforts were made to find methods to prepare infusion solutions with a high energy content and low osmotic pressure. The most realistic alternative seemed to be fat in the form of an emulsion. Many studies of a large number of various fat emulsions were made from the 1920s until the end of the 1950s. However, all of these emulsions caused severe adverse reactions. The first safe fat emulsion, Intralipid, developed by Prof. Arvid Wretlind of the Karolinska Institute, Sweden, was made available for clinical use in 1962. This was the second major step toward TPN. Vitamins, electrolytes, and trace elements were then included in the fat emulsions and in the solutions of amino acids and glucose. Later in the 1960s, Dr. Stanley Dudrick, who as a surgical resident in the University of Pennsylvania, working in the basic science laboratory of Dr.
The Moscow Institute of Physics and Technology, also known as Phystech, has taught numerous Nobel Prize winners, including Pyotr Kapitsa, Nikolay Semyonov, Lev Landau, and Alexander Prokhorov the Fyodorov Eye Microsurgery Complex, founded in 1988 by Russian eye surgeon Svyatoslav Fyodorov the Moscow Aviation Institute the Moscow Motorway Institute (State Technical University) the Moscow Engineering Physics Institute, known for its research in nuclear physics the Combined Arms Academy of the Armed Forces of the Russian Federation, Russia's highest military school Although Moscow has a number of well-known Soviet-era higher educational institutions—most of which are oriented towards engineering or fundamental sciences—in recent years, the city has a growing number of commercial and private institutions that offer classes in business and management. Many state institutions have expanded their educational scope and introduced new courses or departments. Institutions in Moscow, like the rest of post-Soviet Russia, have begun to offer new international certificates and postgraduate degrees, including the Master of Business Administration. In addition, student exchange programs with many countries—especially in Europe—have become widespread in Moscow's universities. Finally, schools in Moscow offer seminars, lectures, and courses for corporate employees and businessmen.
Astrocytes help form the physical structure of the brain, and are thought to play a number of active roles, including the secretion or absorption of neural transmitters and maintenance of the blood–brain barrier. The concept of a tripartite synapse has been proposed, referring to the tight relationship occurring at synapses among a presynaptic element, a postsynaptic element, and a glial element.
Sources: en.wikipedia.org
Between 1981 and 1987, the relationship between Noriega and the U.S. grew considerably. It was driven both by the U.S.'s pursuit of its security interests, and Noriega using these as an effective means of gaining favor. The emergence of internal conflicts in Nicaragua and El Salvador between 1979 and 1981 led the Reagan administration to look for allies in the region, including in Panama. Noriega acted as a conduit for U.S. support, including funds and weapons, to the Contra rebels in Nicaragua. He allowed the CIA to establish listening posts in Panama, and also helped the U.S.-backed Salvadoran government against the leftist Salvadoran insurgent Farabundo Martí National Liberation Front. U.S. spy ships used bases in Panama in their operations against the Nicaraguan government, and much of the intelligence gathered by these ships was processed in the U.S. bases in Panama. Noriega permitted these activities despite the Panama Canal treaties restricting the use of the U.S. bases to protecting the canal. Bush, now U.S. vice president, met again with Noriega in December 1983 to discuss support for the Contras. Noriega had a working relationship with U.S. Marine Corps Lieutenant Colonel Oliver North by 1985. Noriega offered to assassinate or sabotage Sandinista leaders in return for North helping Noriega improve his image with the U.S. government. In June 1985 North met with Noriega in Panama and Noriega agreed to train Contra soldiers in Panama for an invasion of Nicaragua in 1986. In return for Panama's support for U.S.
== Clinical benefits == As a first-generation medication, golodirsen is far away from being curative; clinical trial outcomes have demonstrated it to have a marginal effect on ameliorating Duchenne muscular dystrophy pathology. As of December 2019, golodirsen is approved for therapeutic use in the United States, as well as in the countries that automatically recognize the decisions of the US Food and Drug Administration, under the condition that its benefit will be demonstrated in a confirmatory clinical trial.
Source (also referred to as Source 1) is a 3D game engine developed by Valve. It debuted as the successor to GoldSrc in 2004 with the releases of Half-Life: Source, Counter-Strike: Source, and Half-Life 2. Valve used Source in many of their games in the following years, including Team Fortress 2, Counter-Strike: Global Offensive, Dota 2, and the Portal and Left 4 Dead franchises. Other notable third-party games using Source include most games in the Titanfall franchise, Vampire: The Masquerade – Bloodlines, Dear Esther, The Stanley Parable and Garry’s Mod. Valve continues to support several Source games into the present day, and would incrementally release new branches of the engine until it was succeeded by Source 2 in 2015.
== Interactions == Sauvagine has been shown to interact with corticotropin releasing factor receptors 1 and 2, and (as with other CRF-related peptides) is also bound by the corticotropin-releasing factor binding protein.
Having personally experienced a confused night action off Guadalcanal, Lee was not enthusiastic about a night engagement with Japanese surface forces, believing that his crews were not adequately trained for it. Shortly after learning Lee's opinion, Mitscher requested permission from Spruance to move TF 58 west during the night, to reach a launch position at dawn that would allow for a maximum aerial assault on the enemy force. Spruance considered for an hour, then refused Mitscher's request. Mitscher's staff was disappointed with Spruance's decision. Burke later commented: "We knew we were going to have hell slugged out of us in the morning. We knew we couldn't reach them. We knew they could reach us." Spruance's decision was influenced by his orders from Nimitz, who had made it clear that the protection of the invasion fleet was the primary mission of TF 58. Spruance had concerns that the Japanese would attempt to draw his main fleet away from the Marianas with a diversionary force while slipping an attack force in to destroy the landing fleet. Locating and destroying the Japanese fleet was not his primary objective, and he was unwilling to allow the main strike force of the Pacific Fleet to be drawn westward, away from the amphibious forces. Mitscher accepted the decision without comment. Spruance's decision in this matter, although subsequently criticized, was certainly justified; by this point in the war, it was well known that Japanese operational plans frequently relied on the use of decoys and diversionary forces.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.
No national medicines agency has approved melanotan-2 for clinical use. Afamelanotide, a related but distinct peptide, holds a marketing authorisation in the European Union for a rare photosensitivity disorder. Melanotan-2 itself is handled as a laboratory chemical.
Its broad activity across melanocortin receptors makes it a tool for probing pigmentation, appetite and vascular signalling. Early trials recorded skin darkening and other effects that were not the original focus of the work. Those observations generated hypotheses that later studies have examined.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.